Phase 3 trial opens testing benmelstobart-anlotinib vs sunitinib in non-clear cell RCC

Trial opening · ClinicalTrials.gov · 2026-10-20. Number 2 in the UrologyWatch Top 5 for October 25, 2026.

A phase 3 trial will randomize 126 patients with advanced non-clear cell renal cell carcinoma (excluding chromophobe, collecting duct, and medullary subtypes) 2:1 to benmelstobart plus anlotinib versus sunitinib, with progression-free survival as the primary endpoint.

Source: ClinicalTrials.gov

The full October 25, 2026 edition · Today's urology news